Hi-TIDe : LAbCore immunoglobulin discovery and engineering

| Research interest | Research group projects | Selected Publications
 

steven_dunn.jpg

Steven DUNN
Group leader
Human integrated tumor immunology discovery engine (Hi-TIDe)

Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Phone +41 21 692 59 51
Fax +41 21 692 59 95 
Email Steven.dunn@chuv.ch

Ludwig.jpg (Print)

 

 

Research interest

  • The discovery and development (research-to-GMP) of immunoglobulins of high potential therapeutic interest using a variety of formats (IgG, scFv-Fc, CAR, BiTE, TCR-like Ab etc).
  • Novel molecular strategies for targeting solid tumors.
  • The basis of TCR/pMHC recognition and how best to assess/predict potential cross-reactivity of pMHC targeting agents. 

Research group projects

  • Technology/methodology development for the efficient and effective isolation and optimization of ‘warhead’ binder molecules using phage-display library technology. How best to design and construct libraries and to subsequently screen and rank binders for downstream applications?
  • The establishment of a pipeline of novel CAR/BiTE molecules for experimental evaluation and clinical translation.
  • The Investigation of novel non-TCR scaffolds for the stringent and selective targeting of therapeutically relevant pMHC complexes.
  • The optimization and advancement of global LCR therapeutic monoclonal antibody candidates. Current examples are two potential ‘best-in-class’ anti-TGFb mAbs with exquisite selectivity for discrete TGFb isoforms. Such molecules will be investigated both as soluble IgG4 drugs and as potential TME modulatory secreted effectors in an engineered T cell context.
  • The discovery and development of novel TEM1-targeting antibodies. These will be investigated as IgG-ADCs, BiTEs, CARS etc. A collaborative program also involving nuclear medicine and tumor imaging groups. 

Selected Publications

  • Chunsheng Li, Junying Wang, Jia Hu, Yi Feng, Ann-Marie Chacko, Kosei Hasegawa, Xiaohui Peng, Xingmei Duan, Yi Li, Aizhi Zhao, Vladimir R. Muzykantov, Chaitanya R. Divgi, Steven M. Dunn, George Coukos. Development, optimization, and validation of novel anti-TEM1/CD248 antibody reagents for optical imaging in cancer. Oncotarget, 5(16): 6994-7012 (2014)

  • Nathaniel Liddy, Giovanna Bossi, Katherine J Adams, Anna Lissina, Tara M Mahon, Namir J Hassan, Jessie Gavarret, Frayne C Bianchi, Nicholas J Pumphrey, Kristin Ladell, Emma Gostick, Andrew K Sewell, Nikolai M Lissin, Naomi E Harwood, Peter E Molloy,Yi Li, Brian J Cameron, Malkit Sami, Emma E Baston, Penio T Todorov, Samantha J Paston, Rebecca E Dennis, Jane V Harper, Steven M Dunn, Rebecca Ashfield, Andy Johnson, Yvonne McGrath, Gabriela Plesa, Carl H June, Michael Kalos, David A Price, Annelise Vuidepot, Daniel D Williams, Deborah H Sutton & Bent K Jakobsen. Monoclonal TCR-redirected tumour cell killing. Nature Medicine,18 : 980-987 (2012)

  • Angel Varela-Rohena, Peter E. Molloy, Steven M. Dunn, Yi Li, Megan M. Suhoski, Richard G. Carroll, Anita Milicic, Tara Mahon, Deborah H. Sutton,Bruno E. Laugel,Ruth Moysey, Brian J. Cameron, Annelise Vuidepot,Marco E. Purbhoo, David K. Cole, Rodney E. Phillips, Carl H. June, Bent K. Jakobsen, Andrew K. Sewell, and James L. Riley. Control of HIV-1 immune escape by CD8 T-cells expressing enhanced T-cell receptor variants. Nature Medicine, 14: 1390-1395 (2008).

  • Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LY, Li Y, Molloy PE, Dunn SM, Jakobsen BK, Rosenberg SA, Morgan RA  High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognise and kill tumour cell lines. J. Immunol., 179(9):5845-54 (2007).

  • Yi Li, Ruth Moysey, Peter E Molloy, Anne-Lise Vuidepot, Tara Mahon, Emma Baston, Steven Dunn, Nathaniel Liddy, Jansen Jacob, Bent K Jakobsen & Jonathan M Boulter. Directed evolution of human T cell receptors with picomolar affinities by phage display. Nature Biotechnology, 23(3): 349-354 (2005).

Group members

Ch. des Boveresses 155 - CH-1066 Epalinges
Switzerland
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
ludwig_cancer_research-logo.svg universite_de_lausanne-logo.svg chuv-logo.svg